462610-98-6

Basic information

• Product Name: Ethanone, 1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-methoxyphenyl]-
• CAS NO: 462610-98-6
• Molecular Formula: C15H24O3Si
• Molecular Weight: 280.439
• Mol File: 462610-98-6.mol

Chemical Properties

• CAS DataBase Reference: Ethanone, 1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-methoxyphenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-methoxyphenyl]-(462610-98-6)
• EPA Substance Registry System: Ethanone, 1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-methoxyphenyl]-(462610-98-6)

Safety Data

• Hazardous Substances Data: 462610-98-6(Hazardous Substances Data)

Upstream product

• 552-41-0 1-(2-hydroxy-4-methoxyphenyl)ethanone 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 462611-04-7 1-[2-(tert-butyl-dimethyl-silanyloxy)-4-methoxy-phenyl]-decan-1-one 
• 462611-23-0 1-[2-(tert-butyl-dimethyl-silanyloxy)-4-methoxy-phenyl]-3-(4-trifluoromethyl-phenyl)-propane-1,3-dione 
• 462611-21-8 1-[2-(tert-butyl-dimethyl-silanyloxy)-4-methoxy-phenyl]-3-(4-nitro-phenyl)-propane-1,3-dione 
• 462611-02-5 1-[2-(tert-butyl-dimethyl-silanyloxy)-4-methoxy-phenyl]-3-methyl-butan-1-one 
• 552-41-0 1-(2-hydroxy-4-methoxyphenyl)ethanone 

Relevant articles and documents

Synthesis and biological evaluation of some novel 4H-benzopyran-4-one derivatives as nonsteroidal antiestrogens

The preparation and characterization of some novel 2- and 3-substituted-7-methoxy-4H-1-benzopyran-4-one are presented. The synthesized compounds were evaluated for their uterotrophic, antiuterotrophic and antiimplantation activities in mature female albino rats. 3-Benzyl-7-methoxy-4H-1-benzopyran-4-one (14) showed the highest uterotrophic activity (87%) based on dry uterine weight gain. The antifertility activity, as assessed by the post-coital antiimplantation activity test, was of weak potency for most compounds (14-29%). Among the products, the 2-(4′-methoxyphenyl)-7-methoxy-4H-1-benzopyran-4-one (19) exhibited the highest antiestrogenic activity of 65%. It also elicited 31% of the uterotrophic activity of estradiol.

SUBSTITUTED TRICYCLICS AND METHOD OF USE

The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO

The disclosure relates to TAK1 inhibitors, compositions, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula (I), pharmaceutical compositions having a compound of formula (I), and methods of treating or prevent